SCHEMBL23630396

SCHEMBL23630396

CCOC(=O)C(C(=O)OCC)c1ccnc(N2CCN(C(=O)OC(C)(C)C)CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 2/20 0.47
SKP1 P63208 2/20 0.47
SKP2 Q13309 2/20 0.47
GPR119 Q8TDV5 6/20 0.47
LRRK2 Q5S007 1/20 0.45
HPGD P15428 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
WNT3A P56704 1/20 0.45
IDE P14735 1/20 0.44
ACHE P22303 1/20 0.44
MAP4K4 O95819 1/20 0.44
OPRD1 P41143 1/20 0.43
KCNH2 Q12809 1/20 0.43
PIK3CA P42336 1/20 0.43
HTT P42858 1/20 0.43
SMO Q99835 1/20 0.43
RET P07949 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29944433 1.00 CKS1B (0.47) CKS1BSKP1SKP2GPR119LRRK2
SCHEMBL20951269 0.83 PIK3CA (0.65) CKS1BSKP1SKP2GPR119LRRK2
SCHEMBL16347835 0.82 GPR119 (0.50) CKS1BSKP1SKP2GPR119LRRK2
SCHEMBL113805 0.81 GPR119 (0.55) CKS1BSKP1SKP2GPR119LRRK2
SCHEMBL18551089 0.80 CKS1B (0.47) CKS1BSKP1SKP2GPR119LRRK2
SCHEMBL23630383 0.80 PIK3CA (0.48) PIK3CA
SCHEMBL15228419 0.79 GPR119 (0.56) CKS1BSKP1SKP2GPR119LRRK2
SCHEMBL901264 0.77 GPR119 (0.54) CKS1BSKP1SKP2GPR119LRRK2
SCHEMBL18551087 0.77 GPR119 (0.54) CKS1BSKP1SKP2GPR119LRRK2
SCHEMBL3164551 0.77 GPR119 (0.54) CKS1BSKP1SKP2GPR119LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230091042-A1 SMARCA2-VHL DEGRADERS AMGEN INC. (US) 2023-03-23 US disclosed
EP-4087658-A1 SMARCA2-VHL DEGRADERS Amgen Inc. (US) 2022-11-16 EP disclosed
WO-2021142247-A1 SMARCA2-VHL DEGRADERS AMGEN INC. (US) 2021-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230091042-A1 SMARCA2-VHL DEGRADERS VHL, SMARCC2, SMARCC1 CKS1B 1547/4885SKP1 887/4885SKP2 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.